Browse by author
Lookup NU author(s): Dr David Walker
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
ObjectiveThe effectiveness of anakinra (interleukin-1 receptor antagonist) in early rheumatoid arthritis (RA) is unknown. We evaluated the efficacy of anakinra (combined with methotrexate) in a randomised clinical trial of early active RA patients.MethodsThe Combination Anti-Rheumatic Drugs in Early RA-2 (CARDERA-2) trial was a randomised trial of early (duration <1 year) active RA. Patients were randomised to 12 months of: (1) methotrexate or (2) anakinra-methotrexate. Follow-up lasted 2 years. The primary outcome was erosive progression (changes from baseline in modified Larsen scores). Secondary outcomes were changes from baseline in disease activity score on a 28-joint count (DAS28), health assessment questionnaire (HAQ), and quality of life (EQ-5D) scores alongside ACR responder rates.Results154 patients received the allocated intervention (from 259 screened). Similar Larsen score progression was seen at 12 and 24 months in patients receiving anakinra-methotrexate (mean changes from baseline of 2.50 and 5.10, respectively) and methotrexate monotherapy (mean changes from baseline of 4.16 and 5.20, respectively). Lower improvements in DAS28 and HAQ scores were seen at all time points in anakinra-methotrexate treated patients; these were significantly less at 24 months (DAS28 p=0.04; HAQ P=0.02). Significantly lower EQ-5D score increases were seen at 12 months with anakinra-methotrexate (p=0.03). Anakinra-methotrexate was associated with more serious adverse events compared with methotrexate monotherapy (11 vs. 6 patients), although this was not significant (p=0.59).ConclusionAnakinra (combined with methotrexate) is not effective in early, active RA. It provided no clinical benefits beyond methotrexate monotherapy.
Author(s): Scott IC, Ibrahim F, Simpson G, Kowalczyk A, White-Alao B, Hassell A, Plant M, Richards S, Walker D, Scott DL
Publication type: Article
Publication status: Published
Journal: Clinical and Experimental Rheumatology
Year: 2016
Volume: 34
Issue: 1
Pages: 88-93
Online publication date: 10/02/2016
Acceptance date: 02/09/2015
ISSN (print): 0392-856X
ISSN (electronic): 1593-098X
Publisher: Pacini Editore SpA
URL: http://www.clinexprheumatol.org/abstract.asp?a=9346
PubMed id: 26842950